Ixazomib Citrate
CAS No. | 1201902-80-8 | Cat. No. | BCP02411 |
Name | Ixazomib Citrate | ||
Synonyms | MLN-9708;MLN9708;MLN 9708; | ||
Formula | C20H23BCl2N2O9 | M. Wt | 517.12 |
Description | MLN9708 is a selective, orally bioavailable, second-generation proteasome inhibitor. MLN9708 has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib, which we believe plays an important role in its improved tissue distribution. MLN9708 has a larger blood volume distribution at steady state, and analysis of 20S proteasome inhibition and markers of the unfolded protein response confirms that MLN9708 has greater pharmacodynamic effects in tissues than bortezomib. MLN9708 is a second-generation small-molecule proteasome inhibitor being developed for the treatment of a broad range of human malignancies.Upon exposure to aqueous solutions or plasma, MLN9708 rapidly hydrolyzes to its biologically active form MLN2238.MLN2238 is the biologically active form of MLN9708. | ||
Pathways | Protease/Metabolic Enzyme | ||
Targets | Proteasome |
Structure
![](https://img.biochemsafebuy.com/uploads/img/1201902-80-8_BCP02411.png)
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.